Sto Reports Q3 2026 Results, Showing 14% Sales Growth and Improved Margins
What happened
Sto released its interim report for the third quarter of 2026. Net sales rose by 14% to TSEK 30,099, and the gross margin before depreciation on intangible assets reached 74.0%. Although operating expenses totaled TSEK 31,039, EBITDA improved to TSEK -8,026, and earnings per share were SEK -0.07.
From finanznachrichten.de
Why it matters
The company stated that initiatives to strengthen profitability are delivering clear results, citing growth across all regions and strong performance in recurring sensor sales. The improved financial stability could increase Sto's attractiveness as a funding recipient for Otsuka Pharmaceutical.
From finanznachrichten.de
Who's involved
- StoCompany that released the interim financial report for Q3 2026
- Senzime (Sweden)The company whose financial results were reported in the interim report
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Otsuka PharmaceuticalSpeculative
Otsuka Pharmaceutical might benefit from increased funding attractiveness due to Sto's improved financial stability.